AM Biotech Wins CBE Ingredient Innovation Award for ExoGiov® Bio-Pulsed Exosome Technology; Six Products Secure China Cosmetic Registrations, Advancing Global Expansion

Source from: 工商時報  李翊榛

AM Biotech’s proprietary ExoGiov® Bio-Pulsed Exosome Technology has been honored with the Ingredient Innovation Award at the 2026 China Beauty Expo (CBE). In addition to this prestigious recognition, six of the company’s skincare products have successfully obtained cosmetic regulatory approvals in mainland China, marking a significant milestone in its international expansion.

Dr. Ju-Sheng Hsieh, Chairman of AM Biotech, emphasized that three key advantages—non-human-derived sources, room-temperature stability, and function-oriented engineering—have enabled the company to overcome major challenges in the commercialization of exosome technology. With regulatory access to the Chinese market secured, AM Biotech is well-positioned to accelerate its global expansion.

China Beauty Expo (CBE) is one of the world’s leading and most influential exhibitions for the beauty and cosmetics industry. Each year, the event brings together international beauty brands, ingredient suppliers, research institutions, and industry experts to explore innovations in cosmetic ingredients, emerging technologies, and market trends.

AM Biotech received the Ingredient Innovation Award in recognition of its proprietary Bio-Pulsed Technology, which was highly regarded by an international panel of experts for its technological innovation, scientific sophistication, and commercial application potential. The award was officially presented at the 2026 Cosmetic Ingredient Innovation and Application Conference, held at the Hangzhou International Expo Center, where industry experts and representatives gathered to recognize outstanding achievements in cosmetic ingredient innovation.

According to the CBE judging panel, AM Biotech’s Bio-Pulsed Technology precisely modulates cellular conditions associated with microRNA (miRNA) expression, enabling cells to produce exosomes with targeted functional characteristics. This function-oriented engineering approach demonstrates exceptional innovation and versatility across multiple applications.

The judges also highlighted the technology’s strong scientific and regulatory foundation, supported by its International Nomenclature of Cosmetic Ingredients (INCI) designation, Halal certification, peer-reviewed scientific publications, and patent portfolio. These achievements further reinforce the credibility and commercial readiness of ExoGiov® Bio-Pulsed Exosomes.

Regarding ingredient safety, the judging panel placed particular emphasis on the safety profile of the company’s Specific Pathogen-Free (SPF) chicken embryo-derived source materials. AM Biotech has completed rigorous safety assessments required under China’s cosmetic ingredient regulatory framework, including phototoxicity, skin sensitization, acute toxicity, and 28-day repeated-dose toxicity testing. With a reported purity level of 99.99%, ExoGiov® demonstrates the company’s commitment to high standards of ingredient quality and safety.

Another major advantage recognized by the judges is the technology’s ability to address one of the industry’s longstanding challenges: dependence on cold-chain logistics for cell-derived ingredients.

Unlike conventional exosome materials that often require temperature-controlled transportation and storage, ExoGiov® Bio-Pulsed Exosomes offer room-temperature storage stability, helping reduce logistical complexity and storage requirements while improving commercial scalability.

Furthermore, ExoGiov® utilizes mesenchymal cells derived from SPF chicken embryos rather than human-derived materials. This non-human-derived approach helps address regulatory restrictions on human-origin ingredients in many international markets, significantly enhancing the feasibility of incorporating exosome technology into cosmetic formulations and supporting its broader commercialization worldwide.

AM Biotech remains committed to science-driven innovation and evidence-based product development. The company’s research findings have been published in international peer-reviewed scientific journals, while laboratory studies and SGS human efficacy assessments provide supporting evidence for the potential benefits of ExoGiov® Bio-Pulsed Exosomes in skincare and scalp and hair care applications.

Alongside growing international recognition of its ingredient technology, AM Biotech has also achieved an important regulatory milestone. Six of its cosmetic products have successfully obtained the required cosmetic regulatory credentials for the mainland Chinese market, establishing a foundation for market entry and further commercial expansion.

These achievements demonstrate AM Biotech’s comprehensive capabilities across the entire value chain—from proprietary ingredient research and development, safety and efficacy validation, and regulatory documentation to finished-product commercialization and international market entry.

With its award-winning Bio-Pulsed Exosome Technology, scientific validation, and expanding regulatory achievements, AM Biotech continues to strengthen its position as a Taiwan-based biotechnology innovator, bringing advanced exosome solutions to the global beauty and cosmetics industry.